Research programme: respiratory disorder therapeutics - Pulmatrix

Drug Profile

Research programme: respiratory disorder therapeutics - Pulmatrix

Alternative Names: Fluticasone/salmeterol dry powder - Pulmatrix; Itraconazole - Pulmatrix; Levofloxacin dry powder - Pulmatrix; PUR 0400; PUR 0500; PUR 0600; PUR 0700; PUR 1000; PUR 113; PUR 1500; PUR 1700; PUR 1900; Salmeterol/fluticasone dry powder - Pulmatrix; SD 101 - Pulmatrix; SD 102

Latest Information Update: 15 Mar 2017

Price : $50

At a glance

  • Originator Pulmatrix
  • Class Androstadienes; Biological proteins; Fluoroquinolones; Phenethylamines; Small molecules
  • Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Glucocorticoid receptor agonists; Immunomodulators; Lipocortin synthesis agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cystic fibrosis-associated respiratory tract infections
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis-associated respiratory tract infections; Idiopathic pulmonary fibrosis; Respiratory tract infections
  • Research Respiratory tract disorders
  • No development reported Influenza virus infections

Most Recent Events

  • 10 Mar 2017 Pulmatrix plans meetings with EU and US Regulators for clinical development of PUR 1900 for Asthma and Cystic fibrosis-associated respiratory tract infections (Inhalation)
  • 10 Mar 2017 Pulmatrix plans a phase I/Ib safety, tolerability and pharmacodynamics trial of PUR 1900 for Asthma (Inhalation)
  • 17 Jan 2017 PUR 1900 receives Qualified Infectious Disease Product status for Cystic fibrosis-associated respiratory tract infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top